Introduction
The co-occurrence of tuberculosis (TB) and diabetes mellitus (DM) presents a growing public health challenge, particularly in rural areas of developing countries such as China. While TB remains a persistent threat in these regions, the rising prevalence of DM exacerbates the risk of infectious diseases, including TB. Poor glycemic control in diabetic patients significantly increases susceptibility to TB, leading to worse treatment outcomes and higher transmission rates[1]. This paper examines the bidirectional relationship between TB and DM, explores the underlying mechanisms, and highlights the urgent need for integrated healthcare strategies to improve glycemic control and TB prevention in high-risk populations.
Tuberculosis continues to be a major public health concern in developing nations, particularly in rural and underserved communities. Despite global efforts to reduce TB incidence, factors such as poverty, malnutrition, and limited healthcare access sustain its endemicity. Concurrently, the prevalence of diabetes—especially type 2 diabetes—has surged in these regions due to lifestyle changes, urbanization, and dietary shifts.
The intersection of TB and DM creates a dangerous synergy. Diabetic patients exhibit impaired immune responses, making them more susceptible to TB infection and complicating disease management [2]. Furthermore, TB can worsen glycemic control, creating a vicious cycle that complicates treatment outcomes. This paper argues that strengthening diabetes management and TB control programs is critical to mitigating this dual burden.
The epidemiological link between TB and DM
Multiple studies confirm that DM triples the risk of developing active TB. In China, where both diseases are highly prevalent, rural populations face compounded risks due to delayed diagnoses and inadequate healthcare infrastructure [3].
The bidirectional relationship is evident:
-
1.
DM Increases TB Susceptibility – Chronic hyperglycemia impairs neutrophil and macrophage function, weakening the body's ability to contain Mycobacterium tuberculosis [4].
-
2.
TB Worsens Glycemic Control – Active TB induces systemic inflammation and insulin resistance, destabilizing blood glucose levels in diabetic patients [5].
Challenges in diagnosis and treatment
-
1.
Diagnostic Delays– TB symptoms in diabetic patients may be atypical, leading to misdiagnosis or late detection [6]. Conversely, TB-related weight loss and fatigue can mask uncontrolled diabetes.
-
2.
Therapeutic Complications– Anti-TB drugs (e.g., rifampicin) interact with oral hypoglycemic agents, necessitating careful medication adjustments [7].
-
3.
Higher Relapse Rates– Diabetic TB patients experience longer sputum conversion times and higher treatment failure rates compared to non-diabetic individuals.
Public health implications and solutions
To address this crisis, integrated approaches are essential:
-
1.
Screening Programs – Routine TB screening for diabetic patients (and vice versa) in high-risk areas [8].
-
2.
Glycemic Control Initiatives– Strengthening diabetes management through community health education and affordable insulin access [9].
-
3.
Infection Control Measures– Early detection and isolation of TB cases to reduce transmission, particularly in diabetic populations.
-
4.
Research and Policy Development– Further studies on optimal treatment protocols and advocacy for cross-disciplinary healthcare policies.
Conclusion
The convergence of TB and DM represents a critical yet underappreciated public health threat. Without urgent intervention, the dual burden will continue to escalate, straining healthcare systems in developing nations. A coordinated strategy—combining improved diabetes care, enhanced TB surveillance, and patient education—is vital to breaking this deadly cycle. Policymakers and healthcare providers must prioritize this intersection to safeguard vulnerable populations from this "sweet yet deadly" crisis.
CRediT authorship contribution statement
Fumu Wang: Writing – review & editing, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Haiming Wang: Writing – original draft, Visualization, Validation, Supervision, Software.
Ethical approval
Not applicable.
Consent
Not applicable.
Funding statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- 1.Rehman A.U., Khattak M., Mushtaq U., Rehman M.U., Malik M., Ahmad I. The impact of diabetes mellitus on the emergence of multi-drug-resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis. Front Public Health. 2023;11 doi: 10.3389/fpubh.2023.1244450. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kumar N.P., Sridhar R., Banurekha V.V., Jawahar M.S., Nutman T.B., Babu S. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines. Ann Am Thorac Soc. 2013;10(5):441–449. doi: 10.1513/AnnalsATS.201305-112OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Wang Q., Ma A., Han X., Zhao S., Cai J., Ma Y. Prevalence of type 2 diabetes among newly detected pulmonary tuberculosis patients in China: a community-based cohort study. PLoS ONE. 2013;8(12) doi: 10.1371/journal.pone.0082660. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Restrepo B.I., Schlesinger L.S. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis. 2013;93(Suppl):S10–S14. doi: 10.1016/S1472-9792(13)70004-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kornfeld H., West K., Kane K., Kumpatla S., Zacharias R.R., Martinez-Balzano C., Li W. High prevalence and heterogeneity of diabetes in patients with TB in south India: a report from the effects of diabetes on tuberculosis severity (EDOTS) study. Chest. 2016;149(6):1501–1508. doi: 10.1016/j.chest.2016.02.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Faurholt Jepsen D., Range N., PrayGod G., Jeremiah K., Faurholt-Jepsen M., Aabye M.G., Changalucha J. The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from Mwanza, Tanzania. BMC Infect Dis. 2012;12:165. doi: 10.1186/1471-2334-12-165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nijland H.M., Ruslami R., Stalenhoef J.E., Nelwan E.J., Alisjahbana B., Nelwan R.H., Aarnoutse R.E. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43(7):848–854. doi: 10.1086/507543. [DOI] [PubMed] [Google Scholar]
- 8.Workneh M.H., Bjune G.A., Yimer S.A. Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amhara region, Ethiopia. Infect Dis Poverty. 2016;5:22. doi: 10.1186/s40249-016-0115-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Baker M.A., Harries A.D., Jeon C.Y., Hart J.E., Kapur A., Lönnroth K. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81. doi: 10.1186/1741-7015-9-81. [DOI] [PMC free article] [PubMed] [Google Scholar]